T2 Biosystems Goes Public with $57.2M Stock Offering | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems has launched its initial public offering of 5.2 million shares of common stock at a price of $11 per share, bringing in gross proceeds of $57.2 million.

The Lexington, Mass.-based molecular diagnostics firm said that it has granted the underwriters a 30-day option to purchase an additional 780,000 share at the offering price. It expects to begin trading on the Nasdaq Global market today under ticker symbol "TTOO."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.